Is Moderna Stock a Buy?
Amid the coronavirus outbreak, Moderna (NASDAQ: MRNA) has been making headlines as it works on a vaccine. The stock surged 28% during the Feb. 25 trading session after the biotech company announced the shipment of its vaccine candidate for a phase 1 study. The shares have climbed 55% from the start of the year to their peak earlier this month.
Image source: Getty Images.
Since originating in China in January, the coronavirus has swept its way across the world racking up 118,000 cases so far. The crisis has shaken the stock market -- the S&P 500 has tumbled 15% since the start of the year -- as factory closures, quarantines, and travel warnings have halted activity across sectors. At the same time, investors have flocked to shares of companies like Moderna, which are working on vaccines or treatments to address the virus.
Source Fool.com
